Valneva SE
NASDAQ:VALN

Watchlist Manager
Valneva SE Logo
Valneva SE
NASDAQ:VALN
Watchlist
Price: 9.92 USD 1.54% Market Closed
Market Cap: 690.2m USD

Operating Margin

-33.6%
Current
Declining
by 6.4%
vs 3-y average of -27.2%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-33.6%
=
Operating Income
€-92.4m
/
Revenue
€275m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-33.6%
=
Operating Income
$-92.4m
/
Revenue
€275m

Peer Comparison

Country Company Market Cap Operating
Margin
FR
Valneva SE
PAR:VLA
724.7m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
382B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
160.4B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.6B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.2B USD
Loading...
No Stocks Found

Market Distribution

Lower than 86% of companies in France
Percentile
14th
Based on 2 333 companies
14th percentile
-33.6%
Low
-17 526.7% — 1.3%
Typical Range
1.3% — 11.5%
High
11.5% — 89 700%
Distribution Statistics
France
Min -17 526.7%
30th Percentile 1.3%
Median 6.1%
70th Percentile 11.5%
Max 89 700%

Valneva SE
Glance View

Market Cap
690.2m USD
Industry
Biotechnology

Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

VALN Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-33.6%
=
Operating Income
€-92.4m
/
Revenue
€275m
What is Valneva SE's current Operating Margin?

The current Operating Margin for Valneva SE is -33.6%, which is below its 3-year median of -27.2%.

How has Operating Margin changed over time?

Over the last 3 years, Valneva SE’s Operating Margin has decreased from -31.4% to -33.6%. During this period, it reached a low of -56.5% on Mar 31, 2024 and a high of -1.5% on Mar 31, 2025.

Back to Top